Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers
- PMID: 2052530
- DOI: 10.1023/a:1015810019076
Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers
Abstract
The plasma concentration-time profiles and pharmacokinetics were characterized for nicotine and its major metabolite, cotinine, after multiple daily application of a nicotine user-activated transdermal therapeutic system (UATTS) to nine healthy smokers. The volunteers abstained from smoking 24 hr prior to and during the course of the study. A 10-cm2 system (designed to deliver 75 micrograms/cm2/hr) was applied every 24 hr for 5 days, with serial blood samples taken on Days 1 and 5 and after system removal on Day 5. Generally, the nicotine UATTS was well tolerated. Predose nicotine concentrations on Days 3 to 5 indicated that steady state was reached by Day 3. The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively. There was only slight or no accumulation of nicotine after multiple dosing as indicated by the Day 5 to Day 1 AUC and Cmax ratios of 1.15 (0.09) and 0.98 (0.06), respectively. Overall, the UATTS system maintained relatively constant plasma nicotine concentrations and is suitable for once-daily application.
Similar articles
-
Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System).J Clin Pharmacol. 1993 Feb;33(2):169-74. doi: 10.1002/j.1552-4604.1993.tb03939.x. J Clin Pharmacol. 1993. PMID: 8440767 Clinical Trial.
-
Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers.Pharm Res. 1992 Nov;9(11):1451-5. doi: 10.1023/a:1015862930096. Pharm Res. 1992. PMID: 1475232
-
Pharmacokinetics of nicotine after application of a 30 cm2 nicotine patch under steady-state conditions.Int J Clin Pharmacol Ther Toxicol. 1991 Mar;29(3):92-5. Int J Clin Pharmacol Ther Toxicol. 1991. PMID: 2071260
-
Comparison of the nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) and half-hourly cigarette smoking.J Clin Pharmacol. 1995 Oct;35(10):985-9. doi: 10.1002/j.1552-4604.1995.tb04014.x. J Clin Pharmacol. 1995. PMID: 8568016 Clinical Trial.
-
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005. Treat Respir Med. 2004. PMID: 15350163 Review.
Cited by
-
Pharmacokinetic characterisation of transdermal delivery systems.Clin Pharmacokinet. 1994 Feb;26(2):121-34. doi: 10.2165/00003088-199426020-00005. Clin Pharmacokinet. 1994. PMID: 8162656 Review.
-
Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy.Psychopharmacology (Berl). 2006 Mar;184(3-4):637-44. doi: 10.1007/s00213-005-0184-3. Epub 2005 Nov 1. Psychopharmacology (Berl). 2006. PMID: 16261317 Clinical Trial.
-
Bioavailability and absorption kinetics of nicotine following application of a transdermal system.Br J Clin Pharmacol. 1993 Sep;36(3):221-7. doi: 10.1111/j.1365-2125.1993.tb04221.x. Br J Clin Pharmacol. 1993. PMID: 9114908 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources